Nicholson, Joseph H.
October 1957
Angiology;Oct1957, Vol. 8 Issue 5, p456
Academic Journal
1. The onset of therapeutic hypoprothrombinemia following an initial dose of Coumadin sodium is relatively rapid and predictable from patient to patient. 2. Forecasting of a maintenance dose is relatively easy, and more predictable than with other anticoagulant drugs we have used; the maintenance of therapeutic hypoprothrombinemia is constant in any individual. 3. ‘Escape’ periods are much less with Coumadin sodium than with Dicumarol—6.5 versus 27 per cent. Conversely, the patient derives the benefits of treatment for over 90 per cent of the time during which Coumadin sodium is administered. 4. Excessive depression of prothrombin induced by Coumadin sodium is promptly counteracted by small doses of vitamin K1. 5. Refractiveness to Coumadin sodium following vitamin K does not occur. 6. Coumadin may be given orally as well as parenterally. 7. From these experiences and the reports of others, Coumadin sodium is perhaps the best hypoprothrombinemia-inducing agent available. It deserves wider clinical application in the management of thromboembolic conditions.


Related Articles

  • DICUMAROL: DANGEROUS AND RATHER INEFFECTIVE DRUG. Martorell, Fernando // Angiology;Apr1952, Vol. 3 Issue 2, p185 

    Presents results of the clinical studies of the anticoagulant agent dicumarol. Efficacy of dicumarol for treatment of intravascular coagulation; Advantage of dicumarol over heparin; Consequences and dangers accompanying dicumarol treatment.

  • The Anticoagulant Malingerer. Agle, David P.; Ratnoff, Oscar D.; Spring, Gottfried K. // Annals of Internal Medicine;Jul70, Vol. 73 Issue 1, p67 

    Compares the psychiatric studies of patients who had surreptitiously ingested anticoagulant drugs with those who had taken bishydroxycoumarin in error. Case report of a 27-year-old single nurse with generalized bleeding tendency; Discussion of the criteria for the diagnosis of intoxication with...

  • A case of probable bemiparin-induced heparin-induced thrombocytopenia type II managed with low-dose fondaparinux. Koul, A. N.; Koufakis, T.; Tsapakidis, K.; Margaritis, A.; Gabranis, I. // Journal of Postgraduate Medicine;Oct-Dec2015, Vol. 61 Issue 4, p267 

    A letter to the editor is presented in response to the article "A Case of Probable Hemiparin-Induced Heparin-Induced Thrombocytopenia (HIT) Type II Managed With Low-Dose Fondaparinux" published in a previous issue.

  • dicumarol.  // Taber's Cyclopedic Medical Dictionary;2005, p593 

    A definition of the medical term "dicumarol" is presented, which refers to an anticoagulant drug.

  • Treatment of Venous Leg Ulcers with Sulodexide. Scondotto, Gaetano; Aloisi, Daniele; Ferrari, Patrizio; Martini, Luca // Angiology;Nov1999, Vol. 50 Issue 11, p883 

    Venous ulcers are still today one of the main socioeconomic problems of medical interest in terms of prevalence, morbidity, and costs to the health service. In the past, various studies have been carried out to identify a systemic pharmacologic treatment able to accelerate venous ulcer healing...

  • Are We Using Novel Oral Anticoagulants Wisely? Kuritzky, Louis // Internal Medicine Alert;1/15/2017, Vol. 39 Issue 1, p6 

    The article focuses on a study on efficacy of using novel oral anticoagulants (NOACs) comprised of apixaban, dabigatran, edoxaban, and rivaroxaban, and also mentions their possible side effects.

  • Ministerial support for anticoagulation.  // GP: General Practitioner;5/6/2002, p10 

    Focuses on the initiative taken by Yvette Cooper, health minister of Great Britain and Birmingham, England-based general practitioner David Fitzmaurice to launch a patient support group for people on anticoagulation therapy. Role of the organization Anticoagulation Europe to further progress of...

  • 3 months and 1 year of oral anticoagulant therapy were equivalent for idiopathic proximal deep venous thrombosis.  // ACP Journal Club;Jan/Feb2002, Vol. 136 Issue 1, p11 

    Presents an abstract of the study 'Three Months Versus One Year of Oral Anticoagulant Therapy for Idiopathic Deep Venous Thrombosis,' by G. Agnelli, P. Prandoni, M. G. Santamaria, et. al., and the Warfarin Optimal Duration Italian Trial Investigators, published on the July 19, 2001 issue of the...

  • Quality measurement of anticoagulation care delivery may lead to better outcomes.  // Hem/Onc Today;3/10/2011, Vol. 12 Issue 5, p44 

    The article discusses the results of a research study which indicated that the use of risk-adjusted percent time in therapeutic range data may enhance the credibility of oral anticoagulant care delivery sites.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics